🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Egypt / NCT07521267
Recruiting Not applicable

Nano Coated Orthodontic Miniscrews for en Mass Retraction of the Upper Arch

NCT07521267 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2026-05
Last updated
2026-04-13

Condition(s) studied

Class I MalocclusionMaxillary PrognathismOrthodontic Tooth Movement

Investigational drug(s) / intervention(s)

Silver nanoparticlesuncoated titanium miniscrews

Silver nanoparticles: Patients will receive silver-hydroxyapatite nanocoated titanium miniscrews.These miniscrews will be placed in the maxillary bone for en masse retractonof the upper anterior teeth.

uncoated titanium miniscrews: Patients will receive conventional uncoated titanium miniscrews of the same dimensions and design as the intervention of the group1, but without nano-coating.

Study summary

study will be directed to evaluate silver-hydroxyapatite nano-coated versus uncoated orthodontic miniscrews for en masse retraction of the upper anterior segment.

Eligibility

Sex
ALL
Min age
14 Years
Max age
20 Years
Healthy volunteers
No
Inclusion Criteria: * Class I orthodontic cases with bimaxillary protrusion of the anterior segment of the upper jaw that need at least extraction for orthodontic treatment. * Age 14-20 years. * Good oral hygiene with healthy periodontium. * Need for an absolute skeletal anchorage. * Systemically healthy patients. Exclusion Criteria: * Patient with craniofacial anomalies (e.g, cleft lip and palate) * Presence of systemic diseases or syndromes affecting bone metabolism (e.g, osteoporosis, rickets) * Poor oral hygiene or uncooperative patients. * Extensive dental caries or untreated periodontal disease. * History of trauma or surgery affecting the maxilla or mandible.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Faculty of Dental Medicine (Boys), Al-Azhar University Cairo Cairo Governorate Recruiting

More Al-Azhar University trials in Egypt

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07521267 on ClinicalTrials.gov ↗ ← All trials in Egypt